The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index; 8 of the 21 sources its claims cite were checked for support.
Retinal gene therapy for Stargardt disease with dual AAV intein vectors is both safe and effective in large animal models
Open accessAbstract
Retinal gene therapy using dual adeno-associated viral (AAV) intein vectors can be applied to genetic forms of blindness caused by mutations in genes with coding sequences that exceed single AAV cargo capacity, such as Stargardt disease (STGD1), the most common inherited macular dystrophy. In view of clinical translation of dual AAV intein vectors, here we set to evaluate both the efficiency and safety of their subretinal administration in relevant large animal models. Accordingly, we have developed the first pig model of STGD1, which we found to accumulate lipofuscin similarly to patients. This accumulation is significantly reduced upon subretinal administration of dual AAV intein vectors whose safety and pharmacodynamics we then tested in nonhuman primates, which showed modest and reversible inflammation as well as high levels of photoreceptor transduction. This bodes well for further clinical translation of dual AAV intein vectors in patients with STGD1 as well as for other blinding diseases that require the delivery of large genes.
Overview
CoChat Summary
TL;DR
Dual AAV intein vectors delivering ABCA4 were tested in a newly generated STGD1 pig model and in nonhuman primates. Subretinal administration reconstituted ABCA4, reduced lipofuscin in pigs, and showed high photoreceptor transduction with modest, largely reversible inflammation in NHPs.
Key findings
- A pig STGD1 model was generated by SCNT from Cas9-edited fibroblasts; ABCA4 protein was absent in retinas, and increased RPE lipofuscin was present from 8.5 months, with significant A2E accumulation (*P < 0.001, Welch’s t test) and significantly reduced photopic ERG at 2–3 years.
- In STGD1 pigs, subretinal AAV8.ABCA4.intein vectors (1 × 10^11 GC of each vector per bleb) restored ABCA4 protein to band intensities similar to WT and reduced lipofuscin in treated areas, reaching statistical significance in the highest-transduction areas of pigs treated at 2 years (*P < 0.05).
- In NHPs, AAV8.ABCA4.intein vectors at low dose (1.8 × 10^11 total GC/eye) or high dose (5.6 × 10^11 total GC/eye) transduced 76–99% of photoreceptors in high-transduction regions, spanning on average 61% (range 56–69%) of analyzed retinal sections, with almost total photoreceptor cotransduction.
- NHP ABCA4 protein levels in treated retina punches were on average ~40% above endogenous levels in FB-treated control eyes; ocular inflammation was modest and dose-dependent, with ERG recovery largely complete by week 13 in low-dose eyes and partially complete in high-dose eyes.
Methods
- STGD1 pigs were generated via SCNT from fibroblasts with CRISPR-Cas9 frameshift mutations in ABCA4 exon 2; phenotype was characterized by genotyping, Western blot, retinal histology/fluorescence for lipofuscin and ONL thickness, HPLC for A2E, and ERG.
- Therapeutic efficacy in pigs used subretinal injection of AAV8.GRK1-ABCA4.intein vectors plus AAV8.GRK1-EGFP, with contralateral FB/EGFP control eyes; eyes were harvested 2 months postinjection for Western blot and lipofuscin quantification.
- NHP safety/expression study used 11 female cynomolgus macaques in a 13-week toxicokinetic design with subretinal FB, low-dose, or high-dose AAV8.ABCA4.intein vectors; assessments included ophthalmic examination, ERG, VEP, IOP, fundus photography, OCT, histopathology, BaseScope for intein mRNA, and Simple Western for ABCA4 protein.
Limitations
- The paper states that limited pig numbers prevented definitive conclusions from A2E HPLC and ERG in injected eyes; ERG showed high variability, and eye harvesting/storage in CO2-independent media for 6–10 hours caused a substantial drop in A2E levels even in FB-injected eyes.
- The paper states that the pig efficacy study used aged animals (2–3 years) with ongoing lipofuscin accumulation from at least 8.5 months, a short 2-month postinjection interval, and AAV8, which reaches a transduction plateau only after 7 weeks; whether longer ABCA4 expression in younger pigs could fully normalize lipofuscin remains unknown.
- The paper states the NHP study was not compliant with Good Laboratory Practice, though performed according to scientifically sound principles; the text also makes evident that NHP groups were small (e.g., n = 7 per AAV dose, n = 8 FB) and that some analyses had limited n.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1. Characterization of the STGD1 pig model. (A) Western blot analysis to assess ABCA4 levels in STGD1 (KO) pig retinas derived from different fibroblasts clones. The ID of the clones is indicated above each lane. WT, wild-type. (B) Representative images of retinal cryosections from WT and KO pigs at 10 months of age, showing intense lipofuscin accumulation (red autofluorescence in the RPE layer), in the absence of evident retinal degeneration. RPE, retinal pigment epithelium; ONL, outer nuclear layer; INL, inner nuclear layer. (C) Quantification of lipofuscin accumulation in KO pig retinas via fluorescence microscopy. Lipofuscin autofluorescence was separately evaluated in four regions of the retina, defined according to the known cone density [fig. S3 and (6)]; measurements were done in 8.5-month-old (n = 2; i.e., 63OD and 65OD), 10-month-old (n = 6; i.e., 7OD, 7OS, 14OD, 14OS, 15OD, and 15OS), and 15-month-old (n = 2; i.e., 731OD and 731OS) KO eyes; WT: average lipofuscin levels from n = 6 eyes (i.e., 707OD, 707OS, 850OD, 850OS, 857OD, and 857OS). m.o., month-old. (D) A2E levels in KO pig RPE; measurements were done in 10- to 15-month-old WT (n = 6; i.e., 707OD, 707OS, 850OD, 850OS, 857OD, and 857OS) and KO (n = 8; 7OD, 7OS, 14OD, 14OS, 15OD, 15OS, 731OD, and 731OS) eyes. ***P < 0.001, Welch’s t test. (E) Quantification of ONL thickness in the four retinal regions of KO pig eyes. Measurements were done in 8.5-month-old (n = 2; i.e., 63OD and 65OD), 10–10.5-month-old (n = 8; i.e., 6OD, 7OD, 7OS, 12OD, 14OD, 14OS, 15OD, and 15OS), and 15-month-old (n = 2; i.e., 731OD and 731OS) KO eyes; WT: average levels from n = 6 eyes (i.e., 707OD, 707OS, 850OD, 850OS, 857OD, and 857OS). (F) Measurements of retinal electrical activity via ERG analysis in KO pigs at 2 to 3 years of age. *P < 0.05, Welch’s t test. [(C) to (F)] Data are presented as average ± SEM. Each dot represents a retina.](https://figures.cochat.ai/paper-figures/89717654b249417492860890071092d1/retinal-gene-therapy-for-stargardt-disease-with-dual-aav-intein-vectors-is-both-figure-1.jpg)


![Fig. 4. High levels of retinal transduction following subretinal delivery of AAV8.ABCA4.intein vectors in NHPs. (A) Representative pictures of retinal sections analyzed by BaseScope from NHP eyes at 13 weeks postinjection of either an LD (n = 3) or HD (n = 3) of AAV8.ABCA4.intein vectors or the FB (n = 6). Probes annealing to either the Npu N-intein (dark green dots) or C-intein (red dots) of human.ABCA4.intein mRNAs were used to assess transduction. ONL, outer nuclear layer. (B) ABCA4 protein levels were measured by Simple Western analysis in two retina punches [one superior temporal (black dot) and one superior nasal (gray dot) punch] collected from the injected bleb area of eyes receiving either a subretinal injection of AAV8.ABCA4.intein at the LD (n = 2) or HD (n = 2) or FB (n = 1) as control. ABCA4 protein levels were normalized to the endogenous control (PDE6B) and then expressed as percentage (%) of ABCA4 protein levels in AAV8.ABCA4.intein-treated versus FB-treated areas. Columns represent mean values for group of treatment, whereas dots represent value of each retina punch. Data are reported as means ± SEM.](https://figures.cochat.ai/paper-figures/55aefcbe59f14246adc9ab83c6c34377/retinal-gene-therapy-for-stargardt-disease-with-dual-aav-intein-vectors-is-both-figure-4.jpg)
Verification
Claims the paper makes
7 Valid · 0 Not valid · 12 Not checked · 73 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“AAV8 vectors were used because of their high transduction efficiency in photoreceptors (24).”
§ Retinal gene therapy for Stargardt disease with dual AAV intein vectors is both safe and effective in large animal models > MATERIALS AND METHODS > Subretinal injection of AAV-intein vectors in STGD1 pigs
What the sources say
- Supportedcites [24] C. Mussolino, M. Della Corte, S. Rossi, F. Viola, U. Di Vicino, E. Marrocco, S. Neglia, M. Doria, F. Testa, R. Giovannoni, M. Crasta, M. Giunti, E. Villani, M. Lavitrano, M. L. Bacci, R. Ratiglia, F. Simonelli, A. Auricchio, E. M. Surace, AAV-mediated photoreceptor transduction of the pig cone-enriched retina. Gene Ther. 18, 637– 645 (2011). 21412286 PMC3131697 source
The Results and discussion section reports robust photoreceptor transduction by AAV2/8 in pigs. When injected alone, AAV2/8 produced fivefold higher EGFP expression than AAV2/5, supporting the cited reason for using it. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Upon subretinal AAV administration, split inteins catalyze the seamless joining of the two halves of the ABCA4 protein, thus reconstituting a functional full-length ABCA4 protein in photoreceptors, at levels that largely exceed those achieved via AAV genome recombination by alternative dual AAV-based strategies (5), resulting in therapeutic efficacy in Abca4−/− mice (5).”
§ Retinal gene therapy for Stargardt disease with dual AAV intein vectors is both safe and effective in large animal models > INTRODUCTION
What the sources say
- Supportedcites [5] P. Tornabene, I. Trapani, R. Minopoli, M. Centrulo, M. Lupo, S. de Simone, P. Tiberi, F. Dell’Aquila, E. Marrocco, C. Iodice, A. Iuliano, C. Gesualdo, S. Rossi, L. Giaquinto, S. Albert, C. B. Hoyng, E. Polishchuk, F. P. M. Cremers, E. M. Surace, F. Simonelli, M. A. De Matteis, R. Polishchuk, A. Auricchio, Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina. Sci. Transl. Med. 11, eaav4523 (2019). 31092694 PMC6863751 source
The Results section reports full-length ABCA4 in retinal lysates after subretinal injection of AAV intein vectors and describes the treatment as photoreceptor transduction. Protein sequencing in the Results found that reconstituted ABCA4 precisely matched the wild-type sequence; the Discussion says improvement in the Abca4−/− retinal phenotype strongly suggests the protein was functional. Page numbers were not available in our copy. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“To overcome this limitation, we have recently developed a dual AAV gene therapy approach, which we named “AAV-ABCA4-intein” vectors (5).”
§ Retinal gene therapy for Stargardt disease with dual AAV intein vectors is both safe and effective in large animal models > INTRODUCTION
What the sources say
- Supportedcites [5] P. Tornabene, I. Trapani, R. Minopoli, M. Centrulo, M. Lupo, S. de Simone, P. Tiberi, F. Dell’Aquila, E. Marrocco, C. Iodice, A. Iuliano, C. Gesualdo, S. Rossi, L. Giaquinto, S. Albert, C. B. Hoyng, E. Polishchuk, F. P. M. Cremers, E. M. Surace, F. Simonelli, M. A. De Matteis, R. Polishchuk, A. Auricchio, Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina. Sci. Transl. Med. 11, eaav4523 (2019). 31092694 PMC6863751 source
The Results section states that the authors developed AAV-ABCA4 intein vectors and describes an implementation in which ABCA4 is split between two AAV vectors. This supports the citing sentence’s identification of a dual AAV approach; the source also describes a three-vector version. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“resulting in therapeutic efficacy in Abca4−/− mice (5).”
§ Retinal gene therapy for Stargardt disease with dual AAV intein vectors is both safe and effective in large animal models > INTRODUCTION
What the sources say
- Supportedcites [5] P. Tornabene, I. Trapani, R. Minopoli, M. Centrulo, M. Lupo, S. de Simone, P. Tiberi, F. Dell’Aquila, E. Marrocco, C. Iodice, A. Iuliano, C. Gesualdo, S. Rossi, L. Giaquinto, S. Albert, C. B. Hoyng, E. Polishchuk, F. P. M. Cremers, E. M. Surace, F. Simonelli, M. A. De Matteis, R. Polishchuk, A. Auricchio, Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina. Sci. Transl. Med. 11, eaav4523 (2019). 31092694 PMC6863751 source
The Results section, “Subretinal administration of AAV intein vectors improves the retinal phenotype of STGD1 and LCA10 mouse models,” reports testing the vectors in Abca4−/− mice and finding significantly reduced RPE lipofuscin accumulation in treated eyes compared with negative-control eyes. That improvement supports the claim of therapeutic efficacy in this mouse model. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“at levels that largely exceed those achieved via AAV genome recombination by alternative dual AAV-based strategies (5), resulting in therapeutic efficacy in Abca4−/− mice (5).”
§ Retinal gene therapy for Stargardt disease with dual AAV intein vectors is both safe and effective in large animal models > INTRODUCTION
What the sources say
- Supportedcites [5] P. Tornabene, I. Trapani, R. Minopoli, M. Centrulo, M. Lupo, S. de Simone, P. Tiberi, F. Dell’Aquila, E. Marrocco, C. Iodice, A. Iuliano, C. Gesualdo, S. Rossi, L. Giaquinto, S. Albert, C. B. Hoyng, E. Polishchuk, F. P. M. Cremers, E. M. Surace, F. Simonelli, M. A. De Matteis, R. Polishchuk, A. Auricchio, Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina. Sci. Transl. Med. 11, eaav4523 (2019). 31092694 PMC6863751 source
In Results, under “AAV intein vectors mediate expression of large therapeutic proteins in vitro and in the retina” (page unavailable), the paper directly compares ABCA4 reconstitution by intein and conventional dual AAV vectors. The intein ABCA4 band was stronger even though tenfold less lysate was loaded, supporting the claim that its levels largely exceeded those achieved by the alternative strategy. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
55 more claims
Create a free account to see all 92 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 13
- It may state two separate claims as one. 21
- The quote only partly states this claim. 3
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Minimap2: Pairwise alignment for nucleotide sequences
Li, H. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty191 · Cited by 14,807
NanoPack: visualizing and processing long-read sequencing data
De Coster, W., D’Hert, S., Schultz, D. T., Cruts, M., & Van Broeckhoven, C. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty149 · Cited by 3,168
Cell Types of the Human Retina and Its Organoids at Single-Cell Resolution
Cowan, C. S., Renner, M., De Gennaro, M., Gross-Scherf, B., Goldblum, D., Hou, Y., Munz, M., Rodrigues, T. M., Krol, J., Szikra, T., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.013 · Cited by 654
Tornabene, P., Trapani, I., Minopoli, R., Centrulo, M., Lupo, M., de Simone, S., Tiberi, P., Dell’Aquila, F., Marrocco, E., Iodice, C., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4523 · Cited by 192
Self-citationDistribution and Density of Medium- and Short-wavelength Selective Cones in the Domestic Pig Retina
Hendrickson, A., & Hicks, D. (2002) · Experimental Eye Research · doi:10.1006/exer.2002.1181 · Cited by 183 · cited 1×
“To this aim, we have developed a large animal model of STGD1 using pigs, which have an eye size similar to humans, comparable rod/cone ratio, and the presence of a cone-rich region adjacent to the optic nerve, the so-called visual streak, which resembles the human macula ( 6 ).”
Lenis, T. L., Hu, J., Ng, S. Y., Jiang, Z., Sarfare, S., Lloyd, M. B., Esposito, N. J., Samuel, W., Jaworski, C., Bok, D., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802519115 · Cited by 158
AAV8 Can Induce Innate and Adaptive Immune Response in the Primate Eye
Reichel, F. F., Dauletbekov, D. L., Klein, R., Peters, T., Ochakovski, G. A., Seitz, I. P., Wilhelm, B., Ueffing, M., Biel, M., Wissinger, B., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.018 · Cited by 145
Research works printed but not linked: 1
- E. R. Burnight, L. A. Wiley, D. Ochoa, K. Varzavand, S. Seo, I. Han, R. F. Mullins, E. M. Stone, B. A. Tucker, A dual AAV vector approach for the treatment of ABCA4-associated retinal disease. Invest. Ophthalmol. Vis. Sci. 65, 1540–1540 (2024).
Cited by
AAV-based gene therapies for neovascular AMD
Kim, T. H., Kwon, C. Y., Song, J. Y., & Yoo, H. C. (2026) · Gene Therapy · doi:10.1038/s41434-026-00595-4 · Cited by 7
“The integration of multi-target constructs, such as bispeci fi c antibodies [94] or dual-gene cassettes [68], allows simultaneous modulation of multiple disease pathways and can be particularly bene fi cial in complex conditions like nAMD.”
Subretinal Injection Volume Correlates to Persistent Outer Retinal Thinning in the Pig Eye
Seitz, I. P., Nyshchuk, R., Ellederová, Z., Ardan, T., Juhásová, J., Nemesh, Y., Juhás, Š., Drutovič, S., Süßkind, D., Schnichels, S., et al. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.14.27 · Cited by 3
“15 38 From a volume perspective, a study by Annear et al. 39 was potentially suited to investigate the influence of SRV in dogs: nine animals received subretinal injections of rAAV2.hRPE65p.hRPE65 in both eyes.”
Modalities of vision restoration in optic neuropathies and retinal disease
Rubin, B. R., Lavinsky, F., Cain, R., Kuriyan, A. E., Wollstein, G., Zambrano, R., & Schuman, J. S. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101474 · Cited by 1
Almansa-Garcia, A.-C., Armento, A., Cao, B., Petremann-Dumé, A.-S., Salmaso, S., Caliceti, P., Henes, C., Bolz, S., Kilger, E., Süsskind, D., et al. (2026) · BMC Medicine · doi:10.1186/s12916-025-04610-0 · Cited by 3
“These species exhibit higher cone densities and, in the case of NHPs, a fovea, making them suitable for modeling diseases affecting the macula, such as age-related macular degeneration (AMD) and Stargardt disease [16].”
Liu, F., Li, Q., Su, J., Fu, J., Wu, X., Xu, Q., Ren, C., Jin, X., Song, L., Lu, F., et al. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.12.29 · Cited by 4
“15 19–22 In previous study, we developed a high efficiency dual-AAV system that expressed full-length ABCA4 protein by split intein for gene therapy of Stargardt disease.”
Smetana, J. S., Powell, C. R., Bagdadi, N., Ariagno, T. M., Thomas, H., Weinberger, J., Gur, E., & Lennon, C. W. (2026) · Protein Science · doi:10.1002/pro.70768 · Cited by 1
“…techniques continue to be regularly developed, including use of inteins for adeno-associated virus-mediated gene delivery for disease treatment, as well as programmable in vivo protein editing (Beyer et al., 2025; Ferla et al., 2025; Hua et al., 2025; Tasfaout et al., 2024; Zhou et al., 2024).”
Valenzano, R., McDonald, A. J., Gallego, C., Andriessen, C. A., Moustakas, I., Mulder, A. A., Mikkers, H. M. M., Koning, R. I., Mei, H., & Wijnholds, J. (2026) · Stem Cells · doi:10.1093/stmcls/sxag045
“33 Pig models have also been used to test retinal gene therapy with dual-AAV intein vectors, 34 achieving better results over other dual AAV-based strategies.”
Update on the Management of ABCA4 Retinopathy (Stargardt Disease)
Parameswarappa, D. C., Ratra, D., Chattannavar, G., & Padhy, S. K. (2026) · Ophthalmology and Therapy · doi:10.1007/s40123-026-01407-z
“Similarly, large-animal models, including STGD1 pig models, have shown reductions in lipofuscin burden following dual AAV-mediated gene supplementation, with favorable photoreceptor transduction profiles observed in nonhuman primates [59].”
Brillante, S., Volpe, M., Diana, A., Negueruela, S., Molinari, M., Saurino, R., Cipollaro, E., Polishchuk, E., Tenderini, E., Damiano, C., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2504764123 · Cited by 2
Self-citationChilders, M. K., Lau, H.-C., & Tasfaout, H. (2026) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2025.35
Microphysiological systems to accelerate and de-risk AAV gene therapy development
Tornabene, P., Berreur, E., Roth, A., & Kasendra, M. J. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115841
Stargardt disease: progress, enigmas, and prospects for therapeutic intervention
Palmgren, V. A. C., Pindwarawala, M., Hosseinzadeh, A., & Molday, R. S. (2026) · Expert Review of Ophthalmology · doi:10.1080/17469899.2026.2645188 · Cited by 1
Self-citationAAVLINK breaks the cargo barrier
Ting, J. T. (2026) · Cell · doi:10.1016/j.cell.2026.01.005
Cui, M., Cheng, S.-Y., Liang, J., McGowan, J., Xu, M., Xu, G., Luo, L., Wu, J., Harman, C. D., Jacobson, A. L., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.01.029 · Cited by 1
Goddaer, S., Coster, E. D., Callens, E., Caenegem, E. V., den Heule, O. V., Collin, R. W. J., Peynshaert, K., Nieuwerburgh, F. V., Braeckmans, K., & Remaut, K. (2026) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-02036-y · Cited by 2
“More recently, Ferla, et al. [16] applied this approach directly to EYS , using refined co-injection protocols to achieve improved reconstitution fidelity and photoreceptor preservation.”
Protein engineering: status report
Ai, H., Arnold, F. H., Barrick, D., Bayley, H., Brownless, A.-L. R., Campbell, R. E., Castells‐Graells, R., Chaiyen, P., Chica, R. A., Chisholm, L. O., et al. (2026) · Protein Engineering Design and Selection · doi:10.1093/protein/gzag020 · Cited by 3
Zhu, Y., You, G., Jiang, Y., Yin, K., Wang, R., Li, C., Zhang, X., Yan, Z., Ding, M., Guo, W., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202502602r · Cited by 1
“Additional refinements address immune responses associated with repeated administrations through serotype switching [25] or immune-orthogonal Cas9 variants [36], while large gene delivery is enabled by dual/triple vector systems [37, 38].”
Rocha, A. G., Yu, T., Loveland, M., Patel, D. H., & Rodgers, B. D. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01145-3
“These include retinal and eye disease (34–36), segmental bone defects (37), metachromatic leukodystrophy (38), Huntington’s disease (39), heart failure (40, 41), vascular disease (42), muscular dystrophies (43), motor neuron diseases (44) and hypertension (45, 46) among others.”
Metadata
- Authors
- Ferla, R., Pugni, E., Lupo, M., Tiberi, P., Fioretto, F., Perota, A., Duchi, R., Lagutina, I., Gesualdo, C., Rossi, S., Ventrella, D., Elmi, A., McClinton, B., Toomes, C., Xu, T., Molday, R. S., Surace, E. M., Simonelli, F., Bacci, M. L., Galli, C., Memon, M. A., Shams, N., Auricchio, A., & Trapani, I.
- Affiliations
- AAVantgarde Bio srl, Milan, Italy.
- Telethon Institute Of Genetics And Medicine (IT)
- Federico II University Hospital (IT)
- Avantea (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- University of Bologna (IT)
- University of Pisa (IT)
- University of Leeds (GB)
- University of British Columbia (CA)
- Corresponding author
- Trapani, Ivana
- ORCID
- Ferla, Rita
- Lupo, Mariangela
- Tiberi, Paola
- Fioretto, Federica
- Perota, Andrea
- Duchi, Roberto
- Gesualdo, Carlo
- Rossi, Settimio
- Ventrella, Domenico
- Elmi, Alberto
- McClinton, Benjamin
- Toomes, Carmel
- Xu, Tongzhou
- Molday, Robert S.
- Surace, Enrico M.
- Simonelli, Francesca
- Bacci, Maria L.
- Galli, Cesare
- Memon, Muhammad A.
- Shams, Naveed
- Auricchio, Alberto
- Trapani, Ivana
- Venue
- Science Advances
- Published
- 2025-03-28
- Volume
- 11
- Issue
- 13
- Pages
- eadt9354-eadt9354
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC11939046
- OpenAlex
- W4408865117
- Cited by
- 19
- References
- 25
- Citations by year
- 2026: 15 · 2025: 4
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Science Advances (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- Fondazione Telethon
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- Stargardt disease, STGD1, retinal gene therapy, adeno-associated virus vectors, subretinal gene delivery, porcine model, lipofuscin accumulation, macular dystrophy, phototransduction, inflammation, large animal model, non-human primates, gene therapy safety
- MeSH terms
- Stargardt Disease, Dependovirus, Animals, Disease Models, Animal, Genetic Vectors, Humans, Macular Degeneration, Retina, Swine, Genetic Therapy, Inteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.